Key Takeaways, With Data for Maryland FDA approvals vary by drug: There are currently three GLP-1s on the market that the FDA ...

Blood sugar and insulin levels also depend on the vagus nerve. As blood sugar levels rise, the vagus nerve stimulates the ...

Researchers have achieved impressive results in animal studies with a new weight-loss drug that has no GLP-1-style side ...

Individual usage of glucagon like peptide 1 receptor agonists reduced the risk of hospitalization due to alcohol and substance use disorders.

Researchers have discovered that sodium-glucose cotransporter-2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor ...

Researchers explore the therapeutic potential and clinical insights of GP1-RAs in the management of metabolic ...

The US Food and Drug Administration (FDA) has issued warning letters to four companies selling unapproved glucagon-like ...

Shares of Viking Therapeutics (VKTX) are down $2.70, or 6%, to $44.00 in pre-market trading following Merck (MRK) and Chinese biopharmaceutical ...

The US data suggest that the South has seen the greatest shifts, and the highest rate of GLP-1 prescribing per capita.

Nutraceuticals offer potential health benefits, from migraine relief to cognitive support, but safety and regulatory issues ...

Newer glucose-lowering drugs reduce the risk for late-onset seizures and epilepsy by 24%, with GLP-1 RAs cutting the risk by ...